Abcuro

Abcuro takes $200M series C to fund KLRG1 antibody pivotal trial

Abcuro has secured the series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators.

James Waldron Feb 12, 2025 8:30am

Abcuro uses $155M series B to push KLRG1 antibody through clinic

Aug 17, 2023 6:30am

People shaking hands across a desk that has computer and papers on it

Sanofi-backed Abcuro bags $42M to trial KLRG1 immunotherapy

Jan 7, 2021 7:00am